Find Clinical Trials

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter.

Matching Trials

For more detailed information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.
For a key to the icons and text used in the Results column, please click here.
To learn more about our trial annotation process, results assignments, and the criteria used to highlight drugs with promising results, please click here.

  Clinical Trial Phase Eligible Participant Official Title Location Drugs in Trial Results
NCT06072781IIIRecurrent low grade serous ovarian cancerA Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator's Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 301)AZ, CA, CT, FL, IL, MI, MN, MO, NY, OH, OK, OR, PA, TX, VAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AvutometinibCH5126766, Raf/MEK dual kinase inhibitor RO5126766, RO5126766, CKI27, VS-6766RAF and MEK inhibitorClinical Trials
DefactinibVS-6063, PF-04554878, PF-04554878FAK inhibitorClinical Trials
NCT05281471IIIPlatinum resistant or refractory ovarian cancer that must have had prior bevacizumab; at most 24 months since last dose of prior platinum therapy - intraperitoneal infusionA Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec Followed by Platinum-doublet Chemotherapy and Bevacizumab Compared With Physician's Choice of Chemotherapy and Bevacizumab in Women With Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)AL, AZ, CA, FL, IN, MD, MI, MO, NV, NC, OH, OK, PA, SC, TN, WAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonistApproved in Ovarian Cancer
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
CisplatinCACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, PlatosinDNA damaging agentApproved in Ovarian Cancer
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitorApproved in Ovarian Cancer
Liposomal doxorubicinPegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, DoxilTopoisomerase II inhibitorApproved in Ovarian Cancer
Olvimulogene nanivacirepveclight-emitting oncolytic vaccinia virus GL-ONC1, GLV-1h68, GL-ONC1Induces immune response and tumor cell lysisClinical Trials
NCT06175221IIaStage I-IV solid tumors (fresh tumor available)A Prospective, Open-Label, All-Comers Phase IIa Trial of The Tumor Lysate, Particle Only (TLPO) Cancer Vaccine in Solid Tumor MalignanciesSCView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
TLPO vaccineImmune response against tumor associated antigensClinical Trials
NCT05870748II/IIIPlatinum resistant FOLR+ high grade serous ovarian cancer with prior bevacizumab (Phase III)REFRaME-O1: A Phase 2/3 Open-label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin (STRO-002) Versus Investigator's Choice (IC) Chemotherapy in Women With Relapsed Platinum-resistant Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor Alpha (FOLR1)AZ, CA, DC, FL, MD, MA, MN, NE, NM, NY, OH, OK, OR, PA, TX, VAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitorApproved in Ovarian Cancer
Liposomal doxorubicinPegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, DoxilTopoisomerase II inhibitorApproved in Ovarian Cancer
Luveltamab tazevibulinSTRO-002, anti-folate receptor-alpha antibody drug conjugate STRO-002ADC: anti-FRalpha + microtubule destabilizer (SC209)Clinical Trials
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
TopotecanHycamptamine, Hycamtin, TOPOTopoisomerase I inhibitorApproved in Ovarian Cancer
NCT03935893IIAdvanced solid tumorsA Phase 2 Study to Evaluate the Efficacy and Safety of Adoptive Transfer of Autologous Tumor Infiltrating Lymphocytes in Patients With Advanced Solid CancersPAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AldesleukinIL-2R agonistApproved in Other Cancers
Autologous TILsImmune response against tumor associated antigensClinical Trials
CyclophosphamideSendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, CiclofosfamidaDNA damaging agentApproved in Ovarian Cancer
FludarabineFludara Oral, 2-F-ara-AMP, BeneflurDNA synthesis inhibitorApproved in Other Cancers
NCT03693014IIAdvanced solid tumors with dMMR, high TMB or high MSI with limited progression on checkpoint inhibitor treatmentA Phase II Trial of Hypofractionated Radiotherapy in Patients With Limited Progression on Immune Checkpoint BlockadeCT, NJ, NY, PAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cellsApproved in Other Cancers
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cellsApproved in Other Cancers
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
Radiation TherapyIrradiation, Radiotherapy
NCT04771520IIAdvanced solid tumors with c-Kit or PDGFRA mutations (except c-KIT V654A or T670I)Phase 2 Study of Avapritinib in Patients With CKIT or PDGFRA Mutation-Positive Malignant Solid TumorsTXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AvapritinibPDGFRa and c-Kit inhibitorApproved in Other Cancers
NCT04876456IIRecurrent Germ Cell TumorsA Phase II Trial Evaluating the Efficacy of Cabozantinib in the Treatment of Incurable Patients With Refractory Germ Cell TumorsINView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CabozantinibBMS-907351, Cabometyx, XL184, CometriqMulti-targeted RTK inhibitorApproved in Other Cancers
NCT04957615IIAdvanced solid tumors with ARID1A mutationsA Phase II Clinical Trial to Investigate ARID1A Mutation and CXCL13 Expression in the Pre-Treatment Tumor Samples as a Combinatorial Predictive Biomarker for Immune Checkpoint Therapy in Metastatic Solid TumorsTXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT02628067IIAdvanced solid tumors with high MSI or high TMBA Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)NJView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT02896335IIPatients with progressive brain metastases with amplifications in CDK4, CDK6, CCND1, CCND2, CCND3 or CCNE1 or loss of CDKN2AA Phase 2 Study of Palbociclib in Progressive Brain Metastases Harboring Alterations in the CDK PathwayMAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PalbociclibPD-0332991, PD0332991, IbranceCDK4/6 inhibitorApproved in Other Cancers
NCT04983745IIAdvanced solid tumors with somatic mutations in ATM, BARD1, BRCA1/2, BRIP1, CDK12, CHEK1/2, FANCI/L, PALB2, PPP2R2A, RAD51B/C/D or RAD54LA Phase II Trial of Niraparib and Dostarlimab Combination Therapy in Patients With Somatic Homologous Recombination Deficient Advanced or Metastatic CancerTNView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
DostarlimabTSR-042, anti-PD-1 monoclonal antibody TSR-042, ANB011Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NiraparibMK4827, ZejulaPARP inhibitorApproved in Ovarian Cancer
NCT02710253IIAdvanced solid tumors that must have progressed on prior immunotherapy or cellular therapy (amenable to radiation therapy)Phase II Trial of Salvage Radiation Therapy to Induce Systemic Disease Regression After Progression on Systemic ImmunotherapyTXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Radiation TherapyIrradiation, Radiotherapy
NCT05272462IIPlatinum resistant ovarian cancerA Phase II Trial of Oral Minoxidil for the Treatment of Recurrent Platinum Resistant Epithelial Ovarian CancerILView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
MinoxidilKir6/SUR2 channel activatorApproved in Other Indications
NCT05286801IIAdvanced solid tumors with loss of SMARCB1 or SMARCA1A Phase 1/2 Study of Tiragolumab (NSC# 827799) and Atezolizumab (NSC# 783608) in Patients With Relapsed or Refractory SMARCB1 or SMARCA4 Deficient TumorsAL, CA, CO, DC, GA, IL, IN, MD, MA, MI, MN, MO, NY, NC, OH, OR, PA, TN, TX, UT, WA, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cellsApproved in Other Cancers
TiragolumabMTIG7192A, RO7092284Blocks TIGIT binding to PVR (CD155) and PVRL2 (CD112) to enable DNAM-1 (CD226) mediated activation of NK and CD8 T cellsClinical Trials
NCT01174121IIAdvanced solid tumorsA Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphodepleting Regimen in Metastatic Cancers Plus the Administration of PembrolizumabMDView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AldesleukinIL-2R agonistApproved in Other Cancers
CyclophosphamideSendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, CiclofosfamidaDNA damaging agentApproved in Ovarian Cancer
FludarabineFludara Oral, 2-F-ara-AMP, BeneflurDNA synthesis inhibitorApproved in Other Cancers
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
Selected Young TILImmune response against tumor associated antigensClinical Trials
NCT03734692IIPlatinum sensitive ovarian cancer with first or second recurrence in peritoneal cavitySystemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian CancerPAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CisplatinCACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, PlatosinDNA damaging agentApproved in Ovarian Cancer
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
RintatolimodAtvogenTLR3 agonist and immune cell stimulatorApproved in Other Indications
NCT03742895IIAdvanced solid tumors without BRCA1/2 mutations, with Homologous Recombination Repair gene mutations (e.g., ATM, PALB2, RAD51D) or HRD+A Phase 2 Study of Olaparib Monotherapy in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced CancerMD, NJ, NY, WAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
NCT05453825IIPlatinum resistant or refractory ovarian cancerA Phase 2, Multicenter, Open-Label Basket Study of Navicixizumab Monotherapy or in Combination With Paclitaxel or Irinotecan in Patients With Select Advanced Solid TumorsAR, CA, FL, GA, LA, NY, OH, TNView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
NavicixizumabOMP-305B83, anti-DLL4/VEGF bispecific monoclonal antibody OMP-305B83DLL4 and VEGF antagonistClinical Trials
NCT04055649IIPlatinum resistant or refractory ovarian cancer (at most 4 prior therapies for platinum resistant disease)Phase II Study of ONC201 Plus Weekly Paclitaxel in Patients With Platinum-Resistant Refractory or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerMIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
ONC201AKT/ERK inhibitor ONC201, TIC10AKT and ERK kinase inhibitorClinical Trials
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
NCT03462342IIPlatinum sensitive high grade serous ovarian cancer (cohort A), or platinum sensitive high grade serous ovarian cancer with BRCA1/2 mutations or HRD+ w/ clinical benefit of PARPi therapy followed by progression in most recent prior regimen (cohort DII)Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD 6738 and Olaparib in Recurrent Ovarian CancerMD, MA, PAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CeralasertibATR kinase inhibitor AZD6738, AZD6738ATR kinase inhibitorClinical Trials
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
NCT04550494IIAdvanced solid tumors with alterations in ARID1A, ATM, ATR, BAP1, BARD1, BRCA 1/2, BRIP1, CDK12, CHK1/2, FANCA/B/C/D2/E/F/G/I/J/L/M/N, IDH1/2, MRE11A, NBN, PALB2, RAD50/51/51B/51C/51D or RAD54L (only 1 prior platinum therapy; germ-line BRCA MUT patients must have progressed on prior PARP inhibitor)A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage ResponseFL, MD, OKView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
TalazoparibMDV3800, BMN-673, Talazoparib Tosylate, TalzennaPARP inhibitorApproved in Other Cancers
NCT04879121IIAdvanced solid tumors with NTRK1-3 amplifications (at least 7 copies)A Phase II Basket Study of the Oral TRK Inhibitor Larotrectinib (BAY2757556) in Subjects With NTRK Amplification Positive and Pan-TRK Positive TumorsTXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
LarotrectinibTrk inhibitor LOXO-101, LOXO-101, Vitrakvipan-Trk kinase inhibitorApproved in Other Cancers
NCT03310879IIAdvanced solid tumors with CCND1/2/3 alterations or CDK4/6 amplificationsA Phase II Study of the CDK4/6 Inhibitor Abemaciclib in Patients With Solid Tumors Harboring Genetic Alterations in Genes Encoding D-type Cyclins or Amplification of CDK4 or CDK6MAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AbemaciclibBemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, VerzenioCDK4/6 inhibitorApproved in Other Cancers
NCT03428802IIAdvanced solid tumors with high MSI and with POLE, POLD, or BRCA1/2 mutationsA Basket Trial of Pembrolizumab in Patients With Advanced Solid Tumors and Genomic InstabilityNJ, NYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT05634785IIAdvanced CD30+ nonseminomatous germ cell tumorsAdministration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Patients With CD30+ Nonseminomatous Germ Cell Tumors (NSGCT)NCView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
ATLCAR.CD30autologous CD30CAR-CD28-CD3zeta-expressing T lymphocytesImmune response against cancer expressing CD30Clinical Trials
NCT03682289IIAdvanced solid tumors with ARID1A or ATM alterationsPhase II Trial of Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Selected Solid Tumor MalignanciesCAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CeralasertibATR kinase inhibitor AZD6738, AZD6738ATR kinase inhibitorClinical Trials
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
NCT05142241IIRecurrent rare tumorsRapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 2 Talazoparib and TemozolomideMDView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
TalazoparibMDV3800, BMN-673, Talazoparib Tosylate, TalzennaPARP inhibitorApproved in Other Cancers
TemozolomideTemodal, Temodar, MethazolastoneDNA damaging agentApproved in Other Cancers
NCT03579316IIPlatinum sensitive ovarian cancer with BRCA1/2 mutations or HRD+ that must have benefited from and then progressed on prior PARP inhibitorEFFORT: Efficacy of AZD1775 in Parp Resistance; A Randomized 2-Arm, Non-Comparative Phase 2 Study of AZD1775 Alone or AZD1775 and Olaparib in Women With Ovarian Cancer Who Have Progressed During PARP InhibitionMA, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CeralasertibATR kinase inhibitor AZD6738, AZD6738ATR kinase inhibitorClinical Trials
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
NCT05523440IIRecurrent ovarian cancer with ARID1A mutationsPhase 2 Trial of Niraparib or Niraparib and Bevacizumab Combination in Patients With Recurrent Endometrial Cancer and/or Ovarian Cancer With ARID1A Mutation (OU-SCC-ARID1A)OKView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonistApproved in Ovarian Cancer
NiraparibMK4827, ZejulaPARP inhibitorApproved in Ovarian Cancer
NCT05512208IIRecurrent high grade serous, endometrioid or mucinous ovarian cancer with alterations in RAS, BRAF or NF1A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Plus Defactinib (FAK Inhibitor) in Recurrent Gynecological Cancers (DURAFAK)NM, OKView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AvutometinibCH5126766, Raf/MEK dual kinase inhibitor RO5126766, RO5126766, CKI27, VS-6766RAF and MEK inhibitorClinical Trials
DefactinibVS-6063, PF-04554878, PF-04554878FAK inhibitorClinical Trials
NCT05613088IIPlatinum resistant ovarian cancer (at most one prior therapy for platinum resistant disease)A Phase 2 Open-label Randomized Study of Farletuzumab Ecteribulin (MORAb-202), a Folate Receptor Alpha-targeting Antibody-drug Conjugate, Versus Investigator's Choice Chemotherapy in Women With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube CancerCA, CO, FL, MI, NY, NC, OH, WAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Farletuzumab ecteribulinMORAb-202ADC: anti-FRalpha + microtubule destabilizer (eribulin)Clinical Trials
NCT05554380IIAdvanced solid tumors with an activating AKT mutationPhase 2 Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants With AKT-Altered Advanced Non-Breast Solid Tumors: A ComboMATCH Treatment TrialAL, AZ, CA, FL, ID, IL, IA, KY, ME, MD, MI, MN, MT, NV, NY, NC, ND, OH, OK, OR, PA, SD, TX, VA, WA, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
IpatasertibGDC-0068, Akt Inhibitor GDC-0068, RG7440pan-AKT inhibitorClinical Trials
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
NCT05538091IIPlatinum resistant or refractory ovarian cancerPhase II Clinical Trial Combining the Hedgehog Inhibitor Vismodegib With the PD-L1 Inhibitor Atezolizumab in Patients With Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal CancerPAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cellsApproved in Other Cancers
VismodegibHedgehog antagonist GDC-0449, Erivedge, GDC-0449Smoothened antagonistApproved in Other Cancers
NCT05733000IIAdvanced solid tumorsPhase II Open-Label Multi-Cohort Study Evaluating CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Patients With Advanced Chemorefractory Colorectal, Pancreatic, or Other Solid CancersILView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
DevimistatCPI-613, alpha-lipoic acid analogue CPI-613Undisclosed mechanismClinical Trials
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitorApproved in Ovarian Cancer
HydroxychloroquinePlaquenilAutophagy inhibitor
NCT05554328IIRecurrent or persistent ovarian cancer with alterations in BRAF, HRAS, KRAS, NRAS, MEK1/2 or NF1A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients With Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers: A ComboMATCH Treatment TrialAL, AZ, CA, FL, HI, ID, IL, IA, KY, LA, ME, MD, MA, MI, MN, MO, MT, NV, NJ, NM, NY, NC, ND, OH, OK, OR, PA, RI, SD, TX, VA, WA, WV, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
SelumetinibARRY-142886, AZD6244, KoselugoMEK1/2 inhibitorApproved in Other Cancers
NCT04469764IIRecurrent ovarian cancer with CCND1-3 or CDK4/6 amplifications or CDKN2A alterationsAn Open Label Phase II Study of the Efficacy and Safety of Abemaciclib, a Cyclin Dependent Kinase (CDK4/6) Inhibitor in Selected Patients With Recurrent Ovarian or Endometrial CancerCAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AbemaciclibBemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, VerzenioCDK4/6 inhibitorApproved in Other Cancers
AnastrozoleArimidexAromatase inhibitor
LetrozoleFemaraAromatase inhibitorNCCN Guidelines for Ovarian Cancer
NCT05231122IIRecurrent serous, endometrioid or clear cell ovarian cancerRandomized Phase 2 Clinical Trial of Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 in Patients With Recurrent Ovarian CancerNY, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonistApproved in Ovarian Cancer
CDX-1140Stimulates CD40 to increase/activate antigen-presenting cells and enhance immune responseClinical Trials
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT05673928IIAdvanced HER2+ solid tumors with brain metastasesA Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)TXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Trastuzumab emtansinetrastuzumab-MCC-DM1 immunoconjugate, trastuzumab-MCC-DM1 antibody-drug conjugate, trastuzumab-MCC-DM1, trastuzumab-DM1, T-DM1, Kadcyla, ado trastuzumab emtansineADC: anti-HER2 + microtubule destabilizer (DM1)Approved in Other Cancers
TucatinibIrbinitinib, ONT-380HER2 kinase inhibitorApproved in Other Cancers
NCT04992013IIOvarian cancer with brain metastases and alterations in ATM, ATR, BAP1, BARD1, BRCA1/2, BRIP1, MRE11A, NBN, PALB2, RAD50, RAD51B/C/D, RAD54B/L, XRCC2, or XRCC3 (with measurable disease in the CNS)Genomically Guided Phase II Study to Evaluate the Clinical Benefit of Niraparib in Tumors Metastatic to the CNSMAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
NiraparibMK4827, ZejulaPARP inhibitorApproved in Ovarian Cancer
NCT05700721IIAdvanced solid tumors with active brain metastases and with alterations in ATM, BRCA1/2, BRIP1, CDK12, CHEK1/2, FANCL, PALB2, RAD51, RAD51B/C/D, RAD52, or RAD54LPhase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)TXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
DostarlimabTSR-042, anti-PD-1 monoclonal antibody TSR-042, ANB011Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NiraparibMK4827, ZejulaPARP inhibitorApproved in Ovarian Cancer
NCT05465941IIPlatinum resistant high grade serous ovarian cancer; at most one prior line of therapy for platinum resistant diseasePhase II Clinical Trial of PLX038 in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, and Fallopian Tube CancerMNView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PLX038pegylated SN-38 conjugate PLX038Topoisomerase I inhibitorClinical Trials
NCT02675829IIAdvanced solid tumors with HER2 amplificationA Phase 2 Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant CancersNJ, NYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Trastuzumab emtansinetrastuzumab-MCC-DM1 immunoconjugate, trastuzumab-MCC-DM1 antibody-drug conjugate, trastuzumab-MCC-DM1, trastuzumab-DM1, T-DM1, Kadcyla, ado trastuzumab emtansineADC: anti-HER2 + microtubule destabilizer (DM1)Approved in Other Cancers
NCT05601752IIPlatinum resistant high grade serous or endometrioid MAGE-A4+ ovarian cancer that must have had prior bevacizumab; BRCA MUT patients must have received PARP inhibitor therapyA Phase 2, Open-Label, Randomized, Non-Comparative Clinical Trial of ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in Subjects With Recurrent Ovarian CancersAZ, CA, FL, GA, MI, NJ, NC, OH, OK, SD, VA, WAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
Uzatresgene autoleucelautologous genetically-modified MAGE-A4 C1032 CD8alpha T cells, SPEAR T-cell ADP-A2M4CD8, Uza-celImmune response against cancer expressing MAGE-A4Clinical Trials
NCT03994796IIAdvanced solid tumors with brain metastases and NTRK, ROS1, KRAS G12C, CDK pathway or PI3K pathway alterationsGenomically-Guided Treatment Trial in Brain MetastasesAK, AZ, AR, CA, CO, FL, GA, ID, IL, IA, KS, KY, LA, MA, MI, MN, MS, MO, MT, NE, NJ, NY, NC, OH, OK, OR, PA, TX, UT, VT, VA, WA, WI, WYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AbemaciclibBemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, VerzenioCDK4/6 inhibitorApproved in Other Cancers
AdagrasibKRAS G12C inhibitor MRTX849, MRTX849KRAS G12C inhibitorApproved in Other Cancers
EntrectinibRXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, RozlytrekALK, TRK, ROS1 kinase inhibitorApproved in Other Cancers
PaxalisibGDC-0084, PI3K inhibitor GDC-0084, RG7666PI3K/mTOR inhibitorClinical Trials
NCT05467670IIPlatinum resistant ovarian cancer (at most 3 prior therapies for platinum resistant disease)Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Patients With Recurrent Platinum-resistant Ovarian Cancer: Phase II StudyPAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
EvorpaceptCD47/SIRPa-blocking agent ALX148, CD47 antagonist ALX-148, ALX148Blocks CD47 signaling to stimulate immune response and tumor cell phagocytosisClinical Trials
Liposomal doxorubicinPegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, DoxilTopoisomerase II inhibitorApproved in Ovarian Cancer
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT05032040IIPlatinum resistant high grade serous or recurrent clear cell ovarian cancer (at most 2 prior chemotherapy regimens)A Phase 2 Study of XmAb20717 in Patients With Selected Gynecological Malignancies and High-Risk Metastatic Castration-Resistant Prostate CancerCA, FL, GA, MI, NV, NY, PAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
VudalimabXmAb717, anti-PD1/CTLA4 bispecific antibody XmAb20717, XmAb20717Blocks PD-1 and CTLA-4 inhibition of T cellsClinical Trials
NCT04589845IIAdvanced solid tumors with alterations in ALK, ATM, BRAF (class III), KRAS G12C, NTRK1/2/3, PIK3CA (multiple mutations), RET, ROS1 or SETD2Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform TrialCA, CO, FL, GA, ID, MD, MI, MN, MT, NE, NH, NJ, NY, OH, PA, TN, TX, VA, WA, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AlectinibAF802, anaplastic lymphoma kinase inhibitor CH5424802, Alecensa, ALK inhibitor CH5424802ALK kinase inhibitorApproved in Other Cancers
BelvarafenibHM95573BRAF kinase inhibitorClinical Trials
CamonsertibRP-3500ATR kinase inhibitorClinical Trials
DivarasibGDC-6036KRAS G12C inhibitorClinical Trials
EntrectinibRXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, RozlytrekALK, TRK, ROS1 kinase inhibitorApproved in Other Cancers
InavolisibRG6114, GDC-0077PI3K alpha inhibitorClinical Trials
PralsetinibBLU-667RET-kinase inhibitorApproved in Other Cancers
NCT05798611IIAdvanced solid tumors with dMMR or high MSIA Phase II, Open-label, Multi-center, Basket Study of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy to Patients With Biologically Selected Advanced or Metastatic Solid Tumors (ARTIST)CA, IL, MA, NY, OK, PA, RIView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
ART0380ATR kinase inhibitorClinical Trials
NCT03907475IIAdvanced solid tumors (with tumor amenable to skin biopsy)DURVA+ : Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody Durvalumab in Combination With Chemotherapy in Patients With Advanced Solid TumorsMDView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CapecitabineCAPE, XelodaRNA processing and thymidylate synthase inhibitorNCCN Guidelines for Ovarian Cancer
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cellsApproved in Other Cancers
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitorApproved in Ovarian Cancer
Liposomal doxorubicinPegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, DoxilTopoisomerase II inhibitorApproved in Ovarian Cancer
nab-PaclitaxelPaclitaxel Albumin-Stabilized Nanoparticle Formula, Abraxane, ABI-007Microtubule stabilizer/mitotic inhibitorNCCN Guidelines for Ovarian Cancer
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
NCT03026062IIPlatinum resistant or refractory clear cell ovarian cancer or mixed epithelial carcinoma with a clear cell componentRandomized Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab Administered in Combination Versus Sequentially in Recurrent Platinum-Resistant Epithelial Ovarian CancerTXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cellsApproved in Other Cancers
TremelimumabTicilimumab, CP-675206, CP-675,206, CP-675, anti-CTLA4 human monoclonal antibody CP-675,206Blocks CTLA-4 inhibition of T cellsApproved in Other Cancers
NCT05262400IIAdvanced solid tumorsA PHASE 1B/2, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF PF-07220060 IN COMBINATION WITH PF-07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORSCA, MA, MI, MO, TX, WAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AtirmociclibPF-07220060CDK4 inhibitorClinical Trials
PF-07104091CDK2 inhibitorClinical Trials
NCT05071937IIRecurrent ovarian cancer with prior PARP inhibitor (at most 4 prior chemotherapy regimens)Phase ll Study of a BET Inhibitor, ZEN003694, Combined With a PARP Inhibitor, Talazoparib, in Patients With Recurrent Ovarian CancerPAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
TalazoparibMDV3800, BMN-673, Talazoparib Tosylate, TalzennaPARP inhibitorApproved in Other Cancers
ZEN-3694ZEN003694, BET bromodomain inhibitor ZEN-3694BET inhibitorClinical Trials
NCT05715281IIRecurrent rare tumorsRapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 3 Tiragolumab + AtezolizumabMDView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cellsApproved in Other Cancers
TiragolumabMTIG7192A, RO7092284Blocks TIGIT binding to PVR (CD155) and PVRL2 (CD112) to enable DNAM-1 (CD226) mediated activation of NK and CD8 T cellsClinical Trials
NCT04387227IIRecurrent ovarian cancer (only detectable by rising CA125)A Phase II Study of Anti-PD-1 (Pembrolizumab) in Combination With Carboplatin to Prevent Progression After Serologic Detection of Recurrent Ovarian CancerWAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT05787561IIRecurrent or persistent mesonephric or mesonephric-like gynecologic cancer; no prior FAK, RAF or MEK inhibitorSingle Arm Phase II Study of Avutometinib (VS-6766) and Defactinib in Advanced or Recurrent Mesonephric Gynecologic CancerNJ, NYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AvutometinibCH5126766, Raf/MEK dual kinase inhibitor RO5126766, RO5126766, CKI27, VS-6766RAF and MEK inhibitorClinical Trials
DefactinibVS-6063, PF-04554878, PF-04554878FAK inhibitorClinical Trials
NCT06028932IIPlatinum resistant ovarian cancerA Phase II Evaluation of Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-drug Conjugate in Recurrent or Persistent Platinum-resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancersCTView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Sacituzumab govitecanTrodelvy, hrS7-SN38 antibody drug conjugate, anti-TROP-2 Antibody-Drug Conjugate IMMU-132ADC: anti-TROP2 + topoisomerase I inhibitor (SN38)Approved in Other Cancers
NCT05327010IIAdvanced solid tumors with alterations in BARD1, BRCA 1/2, BRIP1, FANCA, PALB2; RAD51 or RAD51C/D with prior PARP inhibitor therapy or advanced solid tumors with a KRAS G12C mutation with prior KRAS G12C targeted therapy or platinum sensitive ovarian cancer without BRCA1/2 mutations with CR/PR on prior PARP inhibitorPhase 2 Trial of the Combination of the BET Inhibitor, ZEN003694 (ZEN-3694), and the PARP Inhibitor Talazoparib, in Patients With Molecularly-Selected Solid Tumors (ComBET)CA, CO, FL, GA, IL, KS, KY, MD, MO, NC, PA, TX, UT, VAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
TalazoparibMDV3800, BMN-673, Talazoparib Tosylate, TalzennaPARP inhibitorApproved in Other Cancers
ZEN-3694ZEN003694, BET bromodomain inhibitor ZEN-3694BET inhibitorClinical Trials
NCT04198766IIAdvanced solid tumorsAn Open-Label, Multicenter, First-in-Human, Dose-Escalation, Multicohort, Phase 1/2 Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid TumorsCA, GA, IL, IA, KY, MI, NE, OR, TN, TX, VA, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
INBRX-106INBRX-106: Hexavalent OX40 AgonistStimulates OX40 to increase T cell activation and immune responseClinical Trials
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT05638295IIAdvanced solid tumors with a KRAS G12C mutationA Randomized Phase II Study of AMG 510 (Sotorasib) With or Without Panitumumab in Advanced Solid Tumors: A ComboMATCH Treatment TrialAL, ID, IL, IA, ME, MI, MO, MT, NV, NM, OH, OK, OR, PA, WA, WIView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PanitumumabVectibix, ABX-EGF, Clone E7.6.3, ABX-EGF Monoclonal AntibodyEGFR antagonist
SotorasibSotorasib, KRAS mutant-targeting AMG 510, AMG 510KRAS G12C inhibitorApproved in Other Cancers
NCT05998135IIPlatinum resistant high grade serous ovarian cancerPhase II Clinical Trial Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian CancerGAView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AtovaquoneApproved in Other Indications
NCT05983276IIRecurrent ovarian cancerCombination of the Hypomethylating Agent Decitabine and the Nuclear Export Receptor XPO-1 Inhibitor Selinexor to Reverse Platinum Resistance in Relapsed/Refractory Epithelial Ovarian CancerILView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
Decitabinedezocitidine, deoxyazacytidine, 5-aza-dCyd, DacogenDNA methylation inhibitorApproved in Other Cancers
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
Selinexorselective inhibitor of nuclear export KPT-330, CRM1 nuclear export inhibitor KPT-330, KPT-330, XpovioSelective inhibition of nuclear export (SINE)Approved in Other Cancers
NCT06005974IIAdvanced solid tumors with APC or AXIN1 mutationsA Phase 2, Open Label Study of REC-4881 in Participants With Unresectable Locally Advanced or Metastatic Cancer With AXIN1 or APC MutationAZ, AR, CA, CT, FL, GA, IL, IN, LA, MD, MA, MO, NE, NV, NJ, NY, ND, OH, OK, OR, PA, SC, SD, TX, UT, VA, WA, WIView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
REC-4881MEK Inhibitor TAK-733, TAK-733MEK1/2 inhibitorClinical Trials
NCT05128825IIPlatinum resistant high grade serous ovarian cancer that must have had prior bevacizumabA Phase 2 Open-Label, Multicenter Study To Evaluate Efficacy And Safety Of ZN-c3 In Subjects With High-Grade Serous Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer (ZN-c3-005/GOG-3066/DENALI)AL, AZ, CA, CO, FL, GA, IL, IN, KY, MD, MA, MN, MO, NE, NV, NJ, NY, NC, OH, OR, PA, SD, TX, UT, VAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AzenosertibZN-c3WEE1 inhibitorClinical Trials
NCT06126276IIAdvanced solid tumors with ERBB2 AMPA Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination With Palbociclib, a CDK4/6 Inhibitor, in Patients With HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment TrialID, IL, IA, ME, MD, MI, MN, MO, MT, NC, OH, OK, OR, PA, TX, WIView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
NeratinibHKI-272, PD272EGFR, HER2, HER4 kinase inhibitorApproved in Other Cancers
PalbociclibPD-0332991, PD0332991, IbranceCDK4/6 inhibitorApproved in Other Cancers
NCT05489211IIAdvanced solid tumorsA Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid TumoursCA, IN, MA, MI, NJ, NM, NY, OH, TN, TX, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
Datopotamab deruxtecanAnti-TROP2/DXd antibody-drug conjugate DS-1062a, Dato-DXdADC: anti-TROP2 + topoisomerase I inhibitor (Dxd)Clinical Trials
SaruparibAZD5305PARP1 inhibitorClinical Trials
NCT05503797IIAdvanced solid cancers with a BRAF fusionA Phase 2 Master Protocol to Assess the Efficacy and Safety of FORE8394, an Inhibitor of BRAF Class 1 and Class 2 Alterations, in Participants With Cancer Harboring BRAF AlterationsCA, FL, MD, MA, MN, MO, NE, NJ, NY, OH, RI, TX, WVView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Plixorafenib8394, BRAF inhibitor PLX8394, FORE8394BRAF kinase inhibitorClinical Trials
NCT06003231IIPlatinum resistant HER2+ ovarian cancerA Phase 2 Basket Study of Disitamab Vedotin in Adult Subjects With Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors That Express HER2AZ, CA, CO, CT, FL, GA, MA, MI, MN, MT, NM, NY, NC, OH, OR, TX, WAView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Disitamab vedotinanti-HER2 ADC RC48, RC48-ADCADC: anti-HER2 + microtubule destabilizer (MMAE)Clinical Trials
NCT03412877IIAdvanced solid tumorsA Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in Patients With Metastatic CancerMDView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AldesleukinIL-2R agonistApproved in Other Cancers
CyclophosphamideSendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, CiclofosfamidaDNA damaging agentApproved in Ovarian Cancer
FludarabineFludara Oral, 2-F-ara-AMP, BeneflurDNA synthesis inhibitorApproved in Other Cancers
Individual Patient TCR-Transduced PBLautologous PBLs retrovirally-transduced with TCRs targeting neoantigensImmune response against neoantigensClinical Trials
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT05185947IIRecurrent or persistent ovarian cancer with peritoneal disease (IP/IV)Phase II Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary CancerMDView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
NilotinibAMN 107, TasignaBcr-abl, c-Kit, and PDGFR kinase inhibitorApproved in Other Cancers
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
NCT04918186IIPlatinum resistant high grade serous ovarian cancer (at most 1 prior therapy for platinum resistant disease)An Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian CancerILView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cellsApproved in Other Cancers
Mecbotamab VedotinCAB-AXL-ADC, BA3011, conditionally active biologic anti-AXL antibody-drug conjugate BA3011ADC: anti-Axl + microtubule destabilizer (MMAE)Clinical Trials
Ozuriftamab VedotinBA3021ADC: anti-ROR2 + microtubule destabilizer (MMAE)Clinical Trials
NCT04919629IIRecurrent ovarian cancer with symptomatic ascites or pleural effusionRandomized Phase 2 Trial of APL-2 With Pembrolizumab vs. APL-2 With Pembrolizumab and Bevacizumab vs. Bevacizumab Alone in Patients With Recurrent Ovarian Cancer and Persistent Malignant EffusionNYView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonistApproved in Ovarian Cancer
PegcetacoplanC3-targeted complement inhibitor APL-2, APL-2Blocks the cleavage of C3Approved in Other Indications
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT05064280IIAdvanced solid tumors with brain metastasesPhase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain MetastasesTXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
LenvatinibMK-7902, Lenvima, ER-203492-00, E7080Multi-targeted RTK inhibitorApproved in Other Cancers
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT05114421IIPlatinum resistant or refractory high grade serous ovarian cancer with disease present in the peritoneal cavity or retroperitoneal lymph nodesImmunomodulation of the Tumor Microenvironment in High-Grade Serous Ovarian Cancer Patients Receiving Pembrolizumab and Lenvatinib Monotherapy and Combination TherapyTXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
LenvatinibMK-7902, Lenvima, ER-203492-00, E7080Multi-targeted RTK inhibitorApproved in Other Cancers
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT06172478IIAdvanced HER3+ solid tumorsHERTHENA-PanTumor01 (U31402-277): A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects With Locally Advanced or Metastatic Solid TumorsCA, MO, TN, TXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Patritumab deruxtecananti-HER3 antibody-drug conjugate U3 1402ADC: anti-HER3 + topoisomerase I inhibitor (Dxd)Clinical Trials
NCT05023655IIAdvanced solid tumors with ARID1A mutationsA Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A MutationSCView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Tazemetostathistone methyl transferase EZH2 inhibitor E7438, EPZ6438, E7438, TazverikEZH2 histone methyltransferase inhibitorApproved in Other Cancers
NCT05296512IIRecurrent or persistent clear cell ovarian cancer or mixed epithelial carcinoma with a clear cell componentA Phase II Trial of Pembrolizumab and Lenvatinib in Patients With Recurrent or Persistent Clear Cell Carcinoma of the OvaryIL, MA, MNView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
LenvatinibMK-7902, Lenvima, ER-203492-00, E7080Multi-targeted RTK inhibitorApproved in Other Cancers
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT05147558IIRecurrent carcinosarcomaA Phase II Trial of Pembrolizumab Plus Lenvatinib for the Treatment of Patients With Advanced Uterine and Ovarian CarcinosarcomasNJ, NYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
LenvatinibMK-7902, Lenvima, ER-203492-00, E7080Multi-targeted RTK inhibitorApproved in Other Cancers
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT05554367IIAdvanced solid tumors with alterations in BRAF, HRAS, KRAS, NRAS or RAF, or low grade serous ovarian cancer with progression on prior MEK inhibitorPalbociclib and Binimetinib in RAS-Mutant Cancers: A ComboMATCH Treatment TrialAL, FL, ID, IL, IA, KY, ME, MD, MA, MI, MN, MO, MT, NM, NY, ND, OH, OK, OR, PA, SC, SD, TX, VA, WA, WV, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BinimetinibMEK162, MEK inhibitor MEK162, ARRY-162, ARRY-438162, MektoviMEK inhibitorApproved in Other Cancers
PalbociclibPD-0332991, PD0332991, IbranceCDK4/6 inhibitorApproved in Other Cancers
NCT02693535IIOvarian expansion for FGFR2 fusion, rearrangement or mutation or Advanced solid tumors with molecular alterations in CDKN2A, CDKN2B, CHEK2, ERBB2, ERBB3, FGFR3, FLT3, KIT, NTRK1/2/3, PALB2, PDGFRA, PDGFRB, POLE, RAF-1, RET, ROS-1, TSC1/2, VEGFR2, VEGFR3, VHL or HER2+Targeted Agent and Profiling Utilization Registry (TAPUR) StudyAL, AZ, CA, CT, FL, GA, IL, IN, ME, MI, NE, NH, NM, NY, NC, ND, OH, OR, PA, SC, SD, TN, TX, UT, VA, WA, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AbemaciclibBemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, VerzenioCDK4/6 inhibitorApproved in Other Cancers
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cellsApproved in Other Cancers
EntrectinibRXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, RozlytrekALK, TRK, ROS1 kinase inhibitorApproved in Other Cancers
FutibatinibTAS-120, FGFR inhibitor TAS-120FGFR1-4 inhibitorApproved in Other Cancers
LarotrectinibTrk inhibitor LOXO-101, LOXO-101, Vitrakvipan-Trk kinase inhibitorApproved in Other Cancers
PalbociclibPD-0332991, PD0332991, IbranceCDK4/6 inhibitorApproved in Other Cancers
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
PertuzumabPerjeta, monoclonal antibody 2C4, rhuMAb2C4HER2 dimerization inhibitorApproved in Other Cancers
PHESGOpertuzumab, trastuzumab, and hyaluronidase-zzxfHER2 antagonistApproved in Other Cancers
RegorafanibBAY73-4506, multikinase inhibitor BAY 73-4506, StivargaMulti-targeted RTK inhibitorApproved in Other Cancers
SunitinibSutent, Sunitinib malateVEGFR2, PDGFR-beta, c-Kit, and FLT3 kinase inhibitApproved in Other Cancers
TalazoparibMDV3800, BMN-673, Talazoparib Tosylate, TalzennaPARP inhibitorApproved in Other Cancers
TemsirolimusTorisel, CCI-779mTOR inhibitorApproved in Other Cancers
TrastuzumabHerceptin, Anti-erbB2 Monoclonal Antibody, HER2 Monoclonal AntibodyHER2 antagonistApproved in Other Cancers
TucatinibIrbinitinib, ONT-380HER2 kinase inhibitorApproved in Other Cancers
NCT05113368IIRecurrent low grade serous ovarian cancerEfficacy of Oral Regorafenib Combined With Intra-muscular Injection of Fulvestrant in Patients With Recurrent Low-grade Serous Ovarian Cancer: A Phase II Single Arm TrialOHView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
FulvestrantZD9238, ICI 182,780, FaslodexER antagonist (SERD)Approved in Other Cancers
RegorafanibBAY73-4506, multikinase inhibitor BAY 73-4506, StivargaMulti-targeted RTK inhibitorApproved in Other Cancers
NCT04449549IIRecurrent rare tumorsRapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and PaclitaxelMDView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
NilotinibAMN 107, TasignaBcr-abl, c-Kit, and PDGFR kinase inhibitorApproved in Other Cancers
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
NCT06281678IIAdvanced solid tumorsA Phase 2, Open-label, Multicenter Study of IBI363 (PD1-IL2m) in Subjects With Advanced Solid MalignanciesTXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
IBI363anti-PD-1/IL-2 bispecific antibody fusion protein IBI363Stimulates IL-2R to increase T and NK cell activation and immune response and blocks PD-L1/2 inhibition of T cellsClinical Trials
NCT05700669Ib/IIRecurrent ovarian cancerA Phase 1b/2 Basket Study To Assess The Safety And Efficacy Of AsiDNA™ In Combination With Olaparib In Participants With Recurrent Solid TumorsTXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AsiDNADNA repair inhibiting oligonucleotideDNA Repair decoyClinical Trials
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
NCT05405595Ib/IIAdvanced solid tumors (Phase II)A Phase 1b/2, Open-Label, Dose Escalation and Expansion Study of ADG126 in Combination With Pembrolizumab (Anti PD-1 Antibody) in Patients With Advanced/Metastatic Solid TumorsAZ, CA, FLView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
ADG126anti-CTLA-4 SAFEbody ADG126, anti-CTLA-4 monoclonal antibody ADG126Blocks CTLA-4 inhibition of T cellsClinical Trials
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT05548296Ib/IIPlatinum resistant high grade serous or endometrioid ovarian cancer with prior bevacizumabA Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination With Gemcitabine in Adult Subjects With Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon OncoSignature® StatusAL, AK, AZ, AR, CA, CO, CT, FL, GA, IL, IA, LA, MD, MA, MI, MO, NJ, NY, NC, OH, OK, OR, PA, RI, SD, TX, UT, VA, WA, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
ACR-368checkpoint kinase 1 inhibitor LY2606368, LY2606368, PrexasertibChk1/2 inhibitorClinical Trials
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitorApproved in Ovarian Cancer
NCT03872947IbRecurrent ovarian cancerA Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations With Selected Anti-Cancer Treatment Regimens in Patients With Selected Advanced Solid TumorsAZ, CA, NJ, NY, OR, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonistApproved in Ovarian Cancer
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitorApproved in Ovarian Cancer
Liposomal doxorubicinPegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, DoxilTopoisomerase II inhibitorApproved in Ovarian Cancer
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
TRK-950monoclonal antibody TRK-950Undisclosed mechanismClinical Trials
NCT04130516I/IIaAdvanced solid tumors with prior PD-1/PD-L1 inhibitor therapy (Phase II)A Multicenter Phase 1-2A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients With Advanced Cancer With and Without PembrolizumabCA, CT, MA, NM, NY, PA, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
LNS8801G protein-coupled estrogen receptor agonist LNS8801GPER agonistClinical Trials
NCT05123482I/IIaRecurrent B7H4+ ovarian cancerA Phase I/IIa Multi-center, Open-label Master Protocol to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Antitumor Activity of AZD8205 in Participants With Advanced or Metastatic Solid MalignanciesCA, MD, MA, MO, NM, NY, NC, PA, TXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AZD8205ADC: anti-B7H4 + topoisomerase I inhibitor (AZ14170132)Clinical Trials
NCT05438329I/IIaPlatinum resistant high grade serous ovarian cancerA Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1305 in Subjects With Advanced/Metastatic Solid TumorsCA, FL, MI, NY, OH, TN, TX, VAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
DB-1305ADC: anti-TROP2 + topoisomerase I inhibitor (P1021)Clinical Trials
NCT04657068I/IIaAdvanced solid tumors with an ATM alteration (Phase II)A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients With Advanced or Metastatic Solid TumorsAL, AR, CO, FL, OK, PA, TN, TX, VAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
ART0380ATR kinase inhibitorClinical Trials
NCT03157128I/IIAdvanced solid tumors with RET alterations (Phase II)A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)AZ, CA, CO, CT, DC, FL, GA, IL, LA, MD, MA, MI, MN, MO, NV, NY, NC, OH, OR, PA, TN, TX, UT, VA, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
SelpercatinibLOXO-292, RET kinase inhibitor LOXO-292, RetevmoRET-kinase inhibitorApproved in Other Cancers
NCT03093116I/IIAdvanced solid tumors with ALK, ROS1 or NTRK1-3 alterations (Phase II)A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)CA, CO, DC, FL, GA, IL, MD, MA, MI, MN, MO, NJ, NY, NC, OH, PA, TN, TX, VA, WA, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
RepotrectinibTPX-0005, ALK/ROS1/NTRK/SRC multi-kinase inhibitor TPX-0005ALK, ROS1, NTRK1-3, SRC and FAK kinase inhibitorApproved in Other Cancers
NCT02068794I/IIPlatinum resistant or refractory ovarian cancer (Phase II)Phase I/II Trial of Intraperitoneal Administration of Adipose Tissue Derived Mesenchymal Stem Cells Infected With a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent Ovarian CancerMNView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
MV-NIS infected mesynchymal stem cellsInduces immune response and tumor cell lysisClinical Trials
NCT02912949I/IIAdvanced solid tumors with a NRG1 gene fusion (Phase II)A Phase I/II Study of MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients With Solid Tumors (eNRGy)CA, DC, FL, GA, IL, MA, MI, MT, NY, PA, TX, UT, VA, WAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Zenocutuzumabanti-HER2/Anti-HER3 bispecific monoclonal antibody MCLA-128, MCLA-128Docks on HER2 and blocks NRG-1 mediated growth of tumor cells by binding to HER3Clinical Trials
NCT03287271I/IIPlatinum resistant or persistent ovarian cancerROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAKCAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
DefactinibVS-6063, PF-04554878, PF-04554878FAK inhibitorClinical Trials
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
NCT03175224I/IIAdvanced solid tumors with MET amplifications or MET gene fusions (Phase II)Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid TumorsCA, DE, FL, MD, MA, MN, MO, NC, OH, PA, SC, TN, TX, WV, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
VebreltinibCBT-101, APL-101, Bozitinibc-Met kinase inhibitorClinical Trials
NCT03190941I/IIAdvanced solid tumors with a RAS G12V mutationA Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 PatientsMDView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AldesleukinIL-2R agonistApproved in Other Cancers
Anti-KRAS G12V mTCR PBLImmune response against cancer expressing RAS G12VClinical Trials
CyclophosphamideSendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, CiclofosfamidaDNA damaging agentApproved in Ovarian Cancer
FludarabineFludara Oral, 2-F-ara-AMP, BeneflurDNA synthesis inhibitorApproved in Other Cancers
NCT05000294I/IIPlatinum resistant or refractory high grade serous or endometrioid ovarian cancerAtezolizumab Plus Tivozanib in Immunologically Cold Tumor TypesFLView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cellsApproved in Other Cancers
TivozanibAV-951VEGFR kinase inhibitorApproved in Other Cancers
NCT05252390I/IIAdvanced solid tumors (NUV-868) or platinum resistant or refractory high grade serous ovarian cancer; patients with BRCA 1/2 mutations or HRD+ must have had prior PARP inhibitor (NUV-868+Olaparib)Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid TumorsAZ, CA, CO, FL, MD, MA, MI, MT, NJ, NY, NC, PA, TN, TX, VAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
NUV-868BRD4 inhibitorClinical Trials
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
NCT05735080I/IIPlatinum resistant or refractory ovarian cancer with CCNE1 AMPA Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of INX-315 in Patients With Advanced CancerGA, MA, NC, OHView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
INX-315CDK2 inhibitorClinical Trials
NCT03767348I/IIAdvanced solid tumor with high MSI or dMMR who have progressed on prior PD-1/PD-L1 inhibitor therapy - intratumoral injection (Phase II)An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid TumorsAZ, AR, CA, FL, IA, KY, MN, NJ, NY, NC, OH, SC, TN, TX, UT, WAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
RP1oncolytic virus RP1, A genetically modified oncolytic viral strain of the herpes simplex type 1 (HSV-1) virusInduces immune response and tumor cell lysisClinical Trials
NCT05252416I/IIPlatinum resistant or refractory ovarian cancer with CCNE1 amplificationA Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients With Advanced Solid TumorsAR, CA, FL, IL, MD, MA, MI, NY, NC, OK, PA, TN, TX, UT, VAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BLU-222CDK2 inhibitorClinical Trials
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
NCT04243499I/IIRecurrent ovarian cancer with high levels of γ9δ2 T cellsA First-in-human, Two-part Clinical Study to Assess the Safety, Tolerability and Activity of IV Doses of ICT01 as Monotherapy and in Combination With a Checkpoint Inhibitor, in Patients With Advanced-stage, Relapsed/Refractory CancerCT, TX, WAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
ICT01Activates gamma/delta T cells to stimulate immune responseClinical Trials
NCT05118789I/IIAdvanced solid tumors with ROS1 rearrangement (Phase II)A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors (ARROS-1)CA, CO, DC, FL, MA, MI, MO, NY, NC, PA, TN, VA, WAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
NVL-520ROS1 kinase inhibitorClinical Trials
NCT04180371I/IIAdvanced solid tumors (Phase II)Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT5528 in Patients With Advanced Malignancies Associated With EphA2 ExpressionCA, CO, FL, MI, NY, OK, PA, RI, TN, TX, VA, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BT5528BT5528 - an EphA2-targeting Bicycle Toxin Conjugate, BT5528-100ADC: anti-EphA2 + microtubule destabilizer (MMAE)Clinical Trials
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT04104776I/IIRecurrent clear cell ovarian cancer with ARID1A mutations and with prior bevacizumab (Phase II)A Phase 1/2 Study of CPI-0209 in Patients With Advanced Solid Tumors and LymphomasGA, IL, MA, MI, NJ, NY, TX, VA, WAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
TulmimetostatCPI-0209, EZH2 inhibitor CPI-0209EZH2 histone methyltransferase inhibitorClinical Trials
NCT04956640I/IIAdvanced solid tumors with a KRAS G12C mutation (Phase II)A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid TumorsAL, CA, CT, FL, IN, LA, MA, NH, NY, NC, PA, TN, TX, UT, VA, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
OlomorasibLY3537982KRAS G12C inhibitorClinical Trials
NCT03564340I/IIPlatinum resistant or refractory ovarian cancer with CA125 levels at least 2 x ULN (Phase II)A Phase 1/2 Study of REGN4018 (A MUC16xCD3 Bispecific Antibody) Administered Alone or in Combination With Cemiplimab in Patients With Recurrent Ovarian Cancer or Other Recurrent MUC16+ CancersAL, MA, MN, NY, OH, OK, TN, VAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Cemiplimabanti-PD-1 monoclonal antibody REGN2810, REGN2810, LibtayoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
SarilumabKevzaraIL-6R antagonistApproved in Other Indications
UbamatamabREGN4018, anti-MUC16/CD3 bispecific antibody REGN4018Re-directs T cells to attack MUC16 (CA125)+ tumor cellsClinical Trials
NCT02484404I/IIRecurrent ovarian cancer (Phase II)Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody Durvalumab (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal CancersMDView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CediranibRecentin, Cediranib maleate, AZD2171VEGFR1-3 kinase inhibitor
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cellsApproved in Other Cancers
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
NCT04718675I/IIPlatinum resistant ovarian cancer (Phase II)Phase 1, First-in-human, Open-label Dose Escalation and Cohort Expansion Study of KB-0742 in Patients With Relapsed or Refractory Solid Tumors or Non-Hodgkin LymphomaCA, IN, MA, MI, MO, OH, PA, TN, TX, VAView Drugs